Insmed stock rises following FDA priority review designation for Arikayce
Insmed's stock experienced a rise after the U.S. Food and Drug Administration (FDA) granted priority review to the company's drug, Arikayce. This development, reported by Investing.com, indicates a faster review process for the drug, which is intended for a specific lung disease.
2 articles from 1 outlet covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
1 outlet covered “Insmed stock rises following FDA priority review designation for Arikayce”. All of them report the following:
- Insmed stock rose
- FDA granted priority review for Arikayce
Which outlets covered this?
All 2 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.
optimist1
pragmatist1